Evidence map›Paper›PMID 33213347›Full record

ArticleCurrent neuropharmacology2021

The Brain-gut Axis-where are we now and how can we Modulate these Connections?

Wojciech Dabrowski, Dorota Siwicka-Gieroba, Katarzyna Kotfis, Sami Zaid, Sylwia Terpilowska, Chiara Robba, Andrzej K Siwicki

Open access · greenAbstract read
In one paragraph

Article in Current neuropharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. The Potential Role of mAntioxidants (Basel, Switzerland) · 2022
    Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Wojciech DabrowskiDepartment of Anesthesiology and Intensive Care, Medical University of Lublin, 20-954 Lublin, Poland.
Dorota Siwicka-GierobaDepartment of Anesthesiology and Intensive Care, Medical University of Lublin, 20-954 Lublin, Poland.
Katarzyna KotfisDepartment of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, 71-204 Szczecin, Poland.
Sami ZaidDepartment of Anaesthesia, Al-Emadi-Hospital Doha, Qatar.
Sylwia TerpilowskaLaboratory of Environmental Biology, Institute of Environmental Engineering, The John Paul II Catholic University of Lublin, 20-950, Lublin, Poland.
Chiara RobbaDepartment of Anaesthesia and Intensive Care, Policlinico San Martino, Genova, Italy.
Andrzej K SiwickiDepartment of Microbiology and Clinical Immunology, University of Warmia and Mazury in Olsztyn, 10-957 Olsztyn, Poland.
Medical University of Lublin · PLAl Emadi Hospital · QAJohn Paul II Catholic University of Lublin · PLOspedale Policlinico San Martino · ITPomeranian Medical University · PLUniversity of Warmia and Mazury in Olsztyn · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A traumatic brain injury (TBI) initiates an inflammatory response with molecular cascades triggered by the presence of necrotic debris, including damaged myelin, hemorrhages and injured neuronal cells. Molecular cascades prominent in TBI-induced inflammation include the release of an excess of proinflammatory cytokines and angiogenic factors, the degradation of tight junctions (TJs), cytoskeletal rearrangements and leukocyte and protein extravasation promoted by increased expression of adhesion molecules. The brain-gut axis consists of a complex network involving neuroendocrine and immunological signaling pathways and bi-directional neural mechanisms. Importantly, modifying the gut microbiome alters this axis, and in turn may influence brain injury and neuroinflammatory processes. In recent years it has been demonstrated that the activity and composition of the gastrointestinal (GI) microbiome population influences the brain through all of above-mentioned pathways affecting homeostasis of the central nervous system (CNS). The GI microbiome is involved in the modulation of cellular and molecular processes which are fundamental to the progression of TBI-induced pathologies, including neuroinflammation, abnormal blood brain barrier (BBB) permeability, immune system responses, microglial activation, and mitochondrial dysfunction. It has been postulated that interaction between the brain and gut microbiome occurs mainly via the enteric nervous system and the vagus nerve through neuroactive compounds including serotonin or dopamine and activation by bacterial metabolites including endotoxin, neurotransmitters, neurotrophic factors, and cytokines. In recent years the multifactorial impact of selected immunomodulatory drugs on immune processes occurring in the CNS and involving the brain-gut axis has been under intensive investigation.

Indexed as

Brain Injuries, TraumaticGastrointestinal MicrobiomeBlood-Brain BarrierBrainCentral Nervous SystemHumanscells interactionsimmunomodulation.microbiomesecondary brain damagetraumaTraumatic brain injury

Identifiers

PMID33213347
PMCPMC8719292
OpenAlexW3098009248

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.